Overview

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
0
Participant gender:
Male
Summary
This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
AstraZeneca
Treatments:
Ketamine
Criteria
Inclusion Criteria:

- BMI 18-30 Non-smoker for at least 4 weeks

Exclusion Criteria:

- Any clinically relevant acute or chronic disease

- History of substance abuse Hypersensitivity to ketamine